Compare · DRTS vs RMD
DRTS vs RMD
Side-by-side comparison of Alpha Tau Medical Ltd. (DRTS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRTS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.86B, about 24.2x DRTS ($1.19B).
- Over the past year, DRTS is up 349.8% and RMD is down 22.9% - DRTS leads by 372.7 points.
- DRTS has been more active in the news (12 items in the past 4 weeks vs 7 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 7 for DRTS).
- Company
- Alpha Tau Medical Ltd.
- ResMed Inc.
- Price
- $13.54+13.78%
- $198.99-1.86%
- Market cap
- $1.19B
- $28.86B
- 1M return
- +44.66%
- +2.60%
- 1Y return
- +349.83%
- -22.85%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 12
- 7
- Recent ratings
- 7
- 25
Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest DRTS
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center
- Chief Financial Officer Levy Raphi sold $31,782 worth of Ordinary Shares (2,270 units at $14.00) and exercised 2,270 units of Ordinary Shares at a strike of $2.98 (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 17,873 units of Ordinary Shares at a strike of $2.98 and sold $232,397 worth of Ordinary Shares (17,873 units at $13.00) (SEC Form 4)
- Chief Financial Officer Levy Raphi exercised 2,127 units of Ordinary Shares at a strike of $2.98 and sold $27,691 worth of Ordinary Shares (2,127 units at $13.02) (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $240,044 worth of Ordinary Shares (20,000 units at $12.00), decreasing direct ownership by 18% to 90,180 units (SEC Form 4)
- Chief Financial Officer Levy Raphi sold $220,004 worth of Ordinary Shares (20,000 units at $11.00), decreasing direct ownership by 15% to 110,180 units (SEC Form 4)
- SEC Form 6-K filed by Alpha Tau Medical Ltd.
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- Chief Financial Officer Levy Raphi sold $167,051 worth of Ordinary Shares (17,500 units at $9.55), decreasing direct ownership by 12% to 130,180 units (SEC Form 4)
Latest RMD
- ResMed downgraded by RBC Capital Mkts with a new price target
- ResMed downgraded by Citigroup with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,090,771 worth of ResMed Common Stock (4,991 units at $218.55) as part of a pre-agreed trading plan (SEC Form 4)
- ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure
- Resmed Announces Agreement to Sell MatrixCare Business
- SEC Form 144 filed by ResMed Inc.
- Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
- ResMed downgraded by Morgan Stanley with a new price target
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)